UNSPSC 51172484: Iduronidase

Iduronidase is an enzyme with the systematic name glycosaminoglycan alpha-L-iduronohydrolase. This enzyme catalyses the hydrolysis of unsulfated alpha-L-iduronosidic linkages in dermatan sulfate and is indicated for people with Mucopolysaccharidosis type 1 (MPS 1).

UNSPSC 51172484 Iduronidase, a Commodity code, names a single enzyme replacement therapy pharmaceutical with no recent state and local procurement activity directly aligned with this specific product. The recent opportunities posted under this code designation include a department relocation notice for Williamson County, Texas (unrelated to procurement), a naloxone and drug deactivation systems solicitation from Seminole County, Florida, a multi-source pharmaceutical RFP from the Minnesota Multistate Cooperative Purchasing Alliance, and several vendor networking events and informational forums across Florida and Texas. Of these, only the MMCAP generic multi-source pharmaceuticals RFP and the Seminole County naloxone procurement represent substantive purchasing activity, but neither targets iduronidase or enzyme replacement therapies specifically. The Seminole County IFB (closing July 26, 2026, based on available documentation) seeks naloxone and drug deactivation systems for community health initiatives; the MMCAP RFP (closing March 26, 2026) targets generic pharmaceuticals and OTC products through three authorized wholesalers for state and local government facilities across multiple states including Oregon, with price competitiveness weighted at 75 percent of evaluation scoring.

State and local buyers appear to use this code infrequently or inconsistently for enzyme replacement therapies—the recent opportunities block reflects significant code-tagging drift toward broader pharmaceutical procurement rather than orphan drug therapies. Geographic activity centers on Florida (Seminole County), Minnesota and Oregon (MMCAP), and Texas (department notice only). The issuing bodies include county health departments, state multistate cooperatives, and regional purchasing coalitions. Without recent hard evidence of direct iduronidase demand in state and local RFPs, RFQs, IFBs, or ITBs, this code signals minimal near-term pursuit activity; vendors focused on rare disease pharmaceuticals or enzyme replacement therapy should monitor cooperative purchasing vehicles and state Medicaid contracts separately rather than rely on this code's current posting pattern.